RxDoctor Payments Data

Jaehoon Chung, MD

Cardiovascular Disease · Rochelle Park, NJNPI 1205138500

Payments from drug & device makers

$6,894in general payments, 2019–2025

Across 264 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$832
  • Novartis$643
  • Heartflow, Inc.$434
  • AstraZeneca$394
  • Amgen$325
  • plus $2K from 43 others

What the payments were for

  • Travel & lodging$1182%
  • Food & beverage$6,58896%
  • Education$1883%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,894 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$311,952
Medicare patients
1,647
Services billed
4,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$355,631
EntrestoSacubitril/Valsartan78$76,174
XareltoRivaroxaban28$40,752
Repatha SureclickEvolocumab28$29,243
BrilintaTicagrelor34$18,233
Repatha PushtronexEvolocumab18$10,720
Praluent PenAlirocumab11$5,591
Atorvastatin Calcium484$5,248
Droxidopa22$5,070
Rosuvastatin Calcium219$5,012
Metoprolol Succinate290$3,557
Ranolazine ErRanolazine32$2,647
Losartan Potassium237$1,546
Amiodarone Hcl43$1,336
Nifedipine ErNifedipine38$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$224$355,631368 claims
NovartisEntresto$643$76,17478 claims
Johnson & JohnsonXarelto$128$40,75228 claims
AstraZenecaBrilinta$394$18,23334 claims
ANI Pharmaceuticals, Inc.Valsartan$20$66123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Rochelle Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →